Neurovascular Devices Market (2033): Neurothrombectomy, Aneurysm Coiling & Stroke Treatment Growth in United States Expansion

DataM Intelligence has released a new research report titled "Neurovascular Devices Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Neurovascular Devices market.

Download Sample Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/neurovascular-devices-market?sindhuri

Recent Key Developments - United States & North America
✅ September 2026: Penumbra expanded its neurovascular thrombectomy portfolio with the launch of LinkTM, a clot-capture device designed to work with its Lightning Bolt® computer-assisted vacuum thrombectomy technology. The device is intended to mechanically engage and hold resistant arterial thrombus while aspiration supports clot ingestion, adding another mechanical clot-engagement option to the thrombectomy workflow.

✅ July 2026: Penumbra reported THUNDER study results for THUNDERBOLTTM, its computer-assisted vacuum thrombectomy system for acute ischemic stroke. The company reported high revascularization rates, short procedure times and low complication rates, while subsequent investigator commentary highlighted complete clot ingestion as an area of focus for improving aspiration thrombectomy.

✅ July 2026: Penumbra began the FORWARD study, enrolling the first patient to evaluate mechanical thrombectomy and computer-assisted vacuum thrombectomy for distal acute ischemic stroke. The study extends computer-assisted aspiration beyond the traditional large-vessel-occlusion setting and is designed to generate clinical evidence for more distal stroke interventions.

Recent Key Developments - Japan & Asia-Pacific
✅ August 2026: Terumo Neuro reported new one-year WISE study analyses for the WEBTM Aneurysm Embolization System, covering both ruptured and unruptured intracranial aneurysm cohorts. The company reported no new bleeds or rebleeds through one year in the analyzed cohorts, adding longer-term clinical evidence around intrasaccular aneurysm treatment.

✅ July-August 2026: Terumo Neuro continued building its evidence-led neurovascular model across international markets, using prospective clinical datasets and physician-facing research programs to support WEB and other neurovascular technologies. The WISE publications released in July and formally highlighted by Terumo Neuro in August included separate analyses of ruptured wide-neck bifurcation aneurysms and unruptured aneurysms.

✅ July 2026: Medtronic and Apollo Hospitals announced an 11-bed advanced ICU facility in Hyderabad, positioned as a clinical innovation hub incorporating Medtronic technologies. While broader than neurovascular devices alone, the development creates a real-world hospital environment for clinical technology deployment and R&D collaboration in India.

Recent Key Developments - Product & Technology Innovation
✅ August 2026: OnyxTM 12 Liquid Embolic System received U.S. FDA approval as part of Medtronic's Onyx portfolio, with a lower-viscosity formulation designed for more distal penetration and a one-minute shake time. The FDA subsequently documented the addition of Onyx 12 to the Onyx product line for middle meningeal artery embolization as an adjunct to surgery for symptomatic subacute or chronic subdural hematoma.

✅ September 2026: Penumbra's THUNDERBOLT platform moved neurovascular technology toward computer-assisted aspiration, using modulated aspiration to support clot detection, ingestion and removal during stroke thrombectomy. The company describes CAVT as a technology platform introduced into its neuro business in 2026, combining computer assistance with continuous vacuum to automate aspects of clot ingestion.

✅ September 2026: FDA approved a labeling change for Stryker Neurovascular's Surpass EliteTM Flow Diverter, updating clinical warnings and the device's Instructions for Use. Separately, FDA records show a September 3 clearance for Terumo Neuro's MayumiTM Thrombectomy System, adding another aspiration thrombectomy system to the U.S. device landscape.

List of Key Players 2026:
Medtronic, Stryker Corporation, Terumo Corporation, MicroPort Scientific Corporation, Johnson & Johnson, Penumbra, Inc., ASAHI INTECC USA, INC., Acandis GmbH, Rapid Medical and NeuroVasc Technologies, Inc.

Company Evaluation
Leading medical device companies such as Medtronic, Stryker, Terumo Corporation and Johnson & Johnson are strengthening their presence in the neurovascular devices market through advanced stroke intervention systems, neurothrombectomy devices, stents, catheters and aneurysm treatment technologies.

Innovative companies such as Penumbra, Acandis and Rapid Medical are advancing neurovascular treatment capabilities through minimally invasive devices, advanced delivery systems and technologies designed to improve access and treatment of complex neurovascular conditions.

Growth Forecast Projected 2026:
The Global Neurovascular Devices Market is anticipated to grow at a considerable rate during the forecast period, between 2026 and 2033. The market was valued at US$3.82 billion in 2024 and is expected to reach US$7.78 billion by 2033, growing at a CAGR of 8.3% during 2025-2033. Rising stroke incidence, technological advancements, and increasing adoption of minimally invasive neurovascular procedures are expected to support market growth over the forecast period.

Get a Customized Industry Report:
https://www.datamintelligence.com/customize/neurovascular-devices-market?sindhuri

M&A / Strategic Activity
Recent acquisitions, partnerships, and ecosystem moves reshaping the Neurovascular Devices Market:

Boston Scientific - Acquisition of Penumbra
In January 2026, Boston Scientific announced a definitive agreement to acquire Penumbra for an enterprise value of approximately $14.5 billion. The transaction gives Boston Scientific a scaled entry into mechanical thrombectomy and neurovascular care, adding Penumbra's stroke revascularization, neuroembolization, and access technologies to its cardiovascular portfolio. The deal was expected to close in 2026, subject to customary conditions.

Medtronic - Acquisition of Scientia Vascular
Medtronic announced the $550 million acquisition of Scientia Vascular in March 2026 and completed the transaction in June 2026. Scientia's guidewires and catheters complement Medtronic's existing thrombectomy, flow-diversion, and embolization portfolio, giving the company greater control over the access portion of neurovascular procedures.

Medtronic - Brainomix Stroke AI Partnership
In February 2025, Medtronic Neurovascular and Brainomix announced a strategic partnership to expand AI-supported stroke imaging across Western Europe. Brainomix 360 Stroke provides automated interpretation of brain imaging to support treatment and transfer decisions, linking imaging triage more closely with endovascular treatment pathways.

Penumbra - Expansion of Computer-Assisted Thrombectomy
Penumbra has been moving computer-assisted vacuum thrombectomy from a peripheral vascular application into neurovascular care. In June 2026, the company received FDA clearance for THUNDERBOLT, followed by European expansion and the launch of the FORWARD study evaluating mechanical thrombectomy and computer-assisted vacuum thrombectomy for distal acute ischemic stroke.

New Product/Device Launches & Deployments
Recent product introductions and commercial deployments changing neurovascular procedures:

Stryker - AXS Lift Intracranial Base Catheter
In June 2025, Stryker launched the AXS Lift Intracranial Base Catheter, designed to provide both intracranial access and stable support from the groin to the cavernous segment of the internal carotid artery. The device is intended to reduce reliance on multiple catheters during complex neurovascular procedures.

Penumbra - RED 72 SILVER LABEL
Penumbra introduced an updated RED 72 SILVER LABEL reperfusion catheter in April 2025. The company reported a 50% increase in trackability versus the original RED 72 with SENDit technology based on its testing, with the redesign focused on navigating the distal anatomy of the brain.

Penumbra - SwiftSET Neuro Embolization Coil
In October 2025, Penumbra launched SwiftSET, a complex embolization coil designed to anchor during deployment and improve vessel-wall apposition in small or tightly shaped spaces. The product extends the company's Swift coil platform for intracranial aneurysms and other neurovascular abnormalities.

Johnson & Johnson MedTech / CERENOVUS - CEREGLIDE 92
CERENOVUS launched the CEREGLIDE 92 Catheter System in the United States in February 2025. Its .092-inch lumen is designed to provide large distal access, flow reduction in the M1 segment during device insertion, and support for multiple neurovascular tools in ischemic and hemorrhagic procedures.

Penumbra - THUNDERBOLT Computer-Assisted Vacuum Thrombectomy
Penumbra's THUNDERBOLT represents a shift from conventional aspiration toward computer-assisted clot detection and ingestion. The company's CAVT platform combines computer control with the Penumbra ENGINE aspiration source, and FDA clearance in June 2026 brought the technology into stroke care.

Scientia Vascular - Expanded Guidewire and Aspiration Portfolio
FDA records show multiple Scientia Vascular neurovascular clearances in 2026, including the Aristotle Mini Guidewire in August, the Aristotle 65 Macrowire in September, and the Socrates 70 Aspiration Catheter in July. These clearances broaden the access and thrombectomy components that are now part of Medtronic's neurovascular portfolio.

R&D & Technological Advancements
Computer-assisted thrombectomy and automated clot ingestion
R&D is moving beyond simply increasing catheter diameter or aspiration force. Penumbra's CAVT approach uses computer-assisted clot detection and controlled vacuum to automate aspects of aspiration thrombectomy. The company's 2026 THUNDER study reported clinical results supporting the safety and effectiveness of THUNDERBOLT, while the FORWARD study is extending evaluation into distal acute ischemic stroke.

AI-assisted stroke imaging and treatment selection
AI is increasingly being positioned directly upstream of thrombectomy rather than as a standalone imaging tool. A large English real-world evaluation involving 452,952 stroke admissions across 107 hospitals examined AI-supported imaging and its relationship with thrombectomy rates and interhospital transfer.

Brainomix's real-world evidence has also linked deployment of its stroke AI platform with increased thrombectomy rates, creating a stronger commercial case for connecting imaging software with stroke-network workflows.

Large-core stroke treatment
The traditional exclusion of patients with large ischemic cores is being challenged by newer clinical evidence. The 2026 American Heart Association/American Stroke Association acute ischemic stroke guideline expands consideration of endovascular thrombectomy to selected patients with larger ischemic cores, widening the population potentially treated with neurovascular devices.

Basilar artery occlusion intervention
The 2026 guideline also provides a strong recommendation for EVT in selected patients with basilar artery occlusion presenting within 24 hours and NIHSS ≥10, creating a clearer clinical pathway for posterior-circulation thrombectomy.

Distal and medium-vessel thrombectomy
Device developers are increasingly testing smaller, more navigable systems for distal occlusions. At the same time, clinical evidence remains unsettled: a 2025 multicenter registry comparing EVT with standard medical management for medium-vessel occlusions highlights that the appropriate role of thrombectomy in M3/M4 and other medium-vessel strokes remains an active clinical question.

Real-time AI inside the angiography workflow
Early research is moving AI from pre-procedure image interpretation into the procedure itself. A 2025 report described real-time AI assistance during mechanical thrombectomy that detected when the guiding catheter moved outside the fluoroscopic image, demonstrating how AI could eventually support procedural navigation rather than only patient selection.

Access technology as a strategic bottleneck
Recent product development increasingly targets guidewires, microcatheters, intermediate catheters, and distal access rather than only the clot-retrieval device. Medtronic's Scientia acquisition specifically addresses this part of the workflow, while FDA records show continued development of specialized Scientia guidewires and aspiration catheters.

Unlock & Gain Complete 360° Market Visibility:
https://www.datamintelligence.com/buy-now-page?report=neurovascular-devices-market?sindhuri

Segments Covered in the Global Neurovascular Devices Market:
By Product
The market includes aneurysm coiling & embolization devices (30%), cerebral balloon angioplasty and stenting systems (22%), support devices (15%), neurothrombectomy devices (25%), and other devices (8%). Aneurysm coiling & embolization devices dominate due to their widespread use in minimally invasive aneurysm treatment, while neurothrombectomy devices are growing rapidly with increasing mechanical thrombectomy adoption for acute ischemic stroke.

By Disease
The market is segmented into aneurysm (30%), ischemic strokes (35%), cerebral aneurysms (18%), arteriovenous malformation and fistulas (10%), and other diseases (7%). Ischemic strokes dominate due to their high global incidence and growing use of endovascular interventions, while aneurysm and cerebral aneurysm treatments continue to drive demand for minimally invasive devices.

By Region
North America - 38% Share
North America leads due to high stroke prevalence, advanced healthcare infrastructure, and strong adoption of minimally invasive neurovascular procedures.

Europe - 27% Share
Europe is supported by increasing stroke awareness, improved access to advanced interventions, and growing adoption of neurovascular technologies.

Asia-Pacific - 23% Share
Asia-Pacific is expanding rapidly due to the rising burden of cerebrovascular diseases, improving healthcare infrastructure, and increasing adoption of advanced neurovascular devices.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.